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A symbiotic glance at the complexities of signature 
microbiomic interventions: Infusing balance
We’re not individuals, we’re colonies of creatures.
Bruce Birren1, Co-director: Genome Sequencing and Analysis Program
The Common Fund’s National Institutes of Health Human Microbiome Project launched in 2007 is the first major 
genomics-based effort to reveal the influence of human microbiota, or resident microorganisms, on the health 
and disease status of humans. The first phase of the Human Microbiome Project (FY2007–2012) focused on 
characterisation of the composition and diversity and evaluation of the metabolic potential of microbiota that inhabit 
five major mucosal surfaces of humans: the oral cavity, gastrointestinal tract, nasal passage, skin and urogenital tract. 
The second and current phase of the Human Microbiome Project (FY2013–2015) is dedicated to data integration of 
the microbe–host biological properties extracted from cohort studies of microbiome-associated diseases.2 
The Human Microbiome Project has provided a few major breakthroughs in understanding the complexity and 
diversity of human microbiota and their role in human health and disease. At present it is estimated that humans 
encompass approximately 20 million genes that encode the entire microbiota. In addition, the microbiota in humans 
contributes immensely toward the micro-xenobiotic and non-xenobiotic interventions inherent to microbiome-
associated diseases. However, there are several issues that require thorough consideration before the scientific 
community can decide on the therapeutic potential of targeting microbiota. This commentary provides a detailed 
incursion into the complicated inter-microbiome associations and interventions that are related to the five 
most researched microbiota in humans: (1) the role of the butyrate-producing microbiome in colorectal cancer 
therapeutics, (2) the protective/defensive microbiome related to inflammatory bowel disease, (3) the risk associated 
with probiotic delivery in obesity, (4) the antimicrobial-based microbiome disproportion leading to/arising from skin 
diseases and (5) the maintenance of microbiome loads and confinement to the vaginal mucosa. 
Microbiomic intervention in colorectal cancer therapy
Muco-adherent pro-inflammatory microbes have been associated with the prevalence of colorectal cancer (CRC).3 
These microbes are carcinogenic and influence the host’s metabolism and function via signalling pathways and 
genotoxicity and by inciting immune responses.3 The colonic microbiome in CRC functions via two specific 
mechanisms – muco-adhesion and muco-inflammation. The muco-adhesion mechanism can be disrupted by 
surgical procedures and the prophylactic administration of antibiotics while the muco-inflammatory mechanism 
may be reduced by the regular use of non-steroidal anti-inflammatory drugs (NSAIDs).4 The prophylactic 
administration of antibiotics also has a negative effect on the beneficial commensal microbiota of the gut. 
Although controversial, the involvement of short-chain fatty acids such as butyrates has been proposed because 
they act via cell-cycle arrest that results in increased apoptosis of carcinogenic cells. Therefore, the introduction 
and preservation of the butyrate-producing microbiome can intervene in CRC therapy.5 Furthermore, it has been 
suggested that carcinogenic (specific to CRC) microbiota have inflammatory niches and hence are further 
influenced by introducing an anti-inflammatory commensal bacterium that is capable of blocking NF-kB expression 
and IL-8 secretion.6 Certain probiotics produce antibacterial peptides that are capable of protecting the host from 
pathogenic commensals and can significantly reduce the occurrence and recurrence of CRC in conjugation with 
a probiotic that is an adhesion competitor (Figure 1). In conclusion, CRC therapy can be effectively intervened by 
administering (1) antibiotics that are selective toward Enterococcus, Streptococcus and Fusobacterium species, 
(2) NSAIDs and (3) anti-inflammatory and butyrate-producing probiotics.
Inflammatory bowel disease and the microbial imbalance
Inflammatory bowel disease (IBD) is associated with an imbalance (preferentially known as dysbiosis) between 
the aggressive and protective microbiome in the gut. This imbalance is mainly an increase in Bacteroides and a 
decrease in Bifidobacterium and Lactobacillus species.7-11 The latter species are prescribed as probiotics in the 
treatment of IBD and their administration may help in correcting the imbalance. However, the efficacy of these 
probiotics in an already compromised inflammatory environment is doubtful and an immediate reduction of the 
aggressive species is required to reverse the imbalance. An interventional strategy involving the administration 
of a purified form of polysaccharide A (a molecule from Bacteroides fragilis) was reported by Mazmanian and 
co-workers8, wherein it was proposed that polysaccharide A can suppress the pro-inflammatory responses in IBD.8 
However, in a recent study, Hueber and co-workers9 stated that suppression of such pro-inflammatory responses 
attained no benefit in severe inflammatory Crohn’s disease even after administering highly potent therapeutic 
agents such as secukinumab. Therefore, broad-spectrum antibiotics such as a combination of ciprofloxacin and 
metronidazole are still the drugs of choice as they are capable of treating IBD complications such as abscesses, 
inflammatory phlegmon, fistulae, fissures, bacterial overgrowth secondary to strictures, prophylactic postoperative 
infections and secondary infections. Furthermore, antimicrobial peptides such as α-defensin 1-4, α-defensin 5, 
β-defensin 1-3, lysozyme, sPLA2, Reg3A/HIP/PAP and lipocalin 2 are significantly effective against Gram-positive 
and Gram-negative pathogenic microbes. They have also shown significant activity against lectins and selective 
bacteria. These antimicrobial peptides can further enhance the composition of the colonising defensive microbiota 
in the gut.10,11
AUTHORS: 
Pradeep Kumar1
Yahya E. Choonara1 
Viness Pillay1
AFFILIATION:
1Wits Advanced Drug Delivery 
Platform Research Unit, 
Department of Pharmacy 
and Pharmacology, School 
of Therapeutic Sciences, 
Faculty of Health Sciences, 
University of the Witwatersrand, 
Johannesburg, South Africa
CORRESPONDENCE TO: 
Viness Pillay
EMAIL: 
viness.pillay@wits.ac.za
POSTAL ADDRESS: 
Department of Pharmacy and 
Pharmacology, University of the 
Witwatersrand Medical School, 
7 York Road, Parktown 2193, 
South Africa
KEYWORDS: 
microbiome; colorectal cancer; 
inflammatory bowel disease; 
obesity; skin microbiome; 
vaginal microbiome
HOW TO CITE:
Kumar P, Choonara YE, Pillay 
V. A symbiotic glance at the 
complexities of signature 
microbiomic interventions: 
Infusing balance. S Afr J 
Sci. 2014;110(11/12), Art. 
#a0089, 5 pages. http://dx.doi.
org/10.1590/sajs.2014/a0089
© 2014. The Author(s).  
Published under a Creative 
Commons Attribution Licence.
2 Volume 110 | Number 11/12November/December 2014
South African Journal of Science  
http://www.sajs.co.za
Commentary Composition and interaction of microbiomic interventions
Page 2 of 5 
Microbiota associated with obesity – 
The probiotic risk
Although controversial, obesity in humans has been microbiotically 
related to the changes in the ratio of Gram-positive Firmicutes and 
Gram-negative Bacteroidetes. However, these studies were performed 
in subjects on restricted diets and hence their findings can be 
debated.12,13 In studies with no dietary restrictions, it has been reported 
that Bacteroidetes significantly differed in obese patients, confirming 
the role of diet in the prevalence of microbiota and obesity.14 It should 
be noted that Firmicutes such as Lactobacillus spp., Bifidobacterium 
spp. and Enterococcus spp. form the majority of functional food and 
therapeutic adjuvants added to farm products as probiotics or prebiotics 
(Figure 2).15 Furthermore, the concentration of live Lactobacillus spp. 
and Bifidobacterium spp. in these functional foods is in the range of 
that used in animals as growth promotors. Surprisingly, the level of 
these adjuvants – especially Lactobacillus acidophilus – in probiotic-
containing dairy foods was enough to cause weight gain in experimental 
piglets. The same is applicable to the weight gain in children on prebiotic 
supplements which contain Lactobacillus rhamnosus – independent 
of disease intervention.16 These findings lead to the conclusion that 
controlling and maintaining the relative abundance of these two bacterial 
species – along with the less researched but dominant archaeon 
Methanobrevibacter smithii – may provide future researchers with drug 
targets for the treatment and prevention of obesity and related disorders.17
Therapeutic intervention of the skin microbiome 
The skin microbiome, constituting mainly Actinobacteria and Proteo-
bacteria, is distributed throughout the human body and differs con-
siderably with respect to external factors such as type of occupation, 
hygiene and climate as well as intrinsic factors such as skin temperature, 
humidity and degree of glandular secretions. For example, sebaceous 
glands are inhabited by Propionbacterineae species, moist areas of 
the skin are colonised by Staphylococcus and Corynebacterium spp., 
while the drier regions are inhabited with Proteobacteria.18 Unique 
to the skin microbiome is the relative inverse abundance correlation 
among various microbial species such as (1) the bacterial deficiency 
of Propionibacterium acnes in the presence of staphylococcal species 
and (2) the relative scarcity of Staphylococcus aureus as a result of 
the abundance of Staphylococcus epidermidis. The staphylococcal 
species and S. epidermidis can be useful probiotics against P. acnes 
and S. aureus, respectively, while also providing prognostic information 
related to these slow dwelling infections.19 However, this entirely 
symbiotic interaction has been adversely affected by the overuse of 
antibiotics, leading to the generation of the highly pathogenic strain of 
methicillin-resistant S. aureus that has acquired genes which are further 
resistant to the antimicrobial peptide released from S. epidermidis.20,21 
The skin microbiome is responsible for various dermatological disorders 
such as atopic dermatitis (S. aureus) and psoriasis (S. pyogenes) caused 
by bacterial infection and seborrheic dermatitis and tinea versicolor 
caused by fungal infection.22 Although antimicrobial interventions have 
shown to be an effective approach for the treatment and prevention of 
these skin disorders, the recovery of the symbiotic microbiome may take 
several weeks and some populations of the microbial community, such 
as S. epidermidis, may never recover to their original concentration.
Vaginal microbiome and related lactobacilli 
abundance and transport
The lactic acid producing microbiome in healthy women consists of 
one of the four species of Lactobacillus, namely L. crispatus, L. iners, 
L. gasseri or L. jensenii.23 The lactic acid produced provides various 
benefits such as acidification of the vaginal milieu (hence preventing 
growth of pathogenic microbes) and modulation of the host vaginal 
membrane and biochemical environment.23 A change in this protecting 
mechanism may lead to the prevalence of pathogenic anaerobic and 
facultative bacteria such as Gardnerella vaginalis, leading to the well-
known condition bacterial vaginosis (BV).24,25 Another important 
opportunistic infection is vaginal candidiasis in which the vaginal 
epithelium is asymptomatically colonised with Candida. These bacterial 
species are also responsible for preterm birth as a result of the passage 
of bacteria to the upper genital tract, for the infrequent problem known 
as vulvovaginal pain, and for increased susceptibility to HIV and other 
sexually acquired infections. Therefore, therapeutic opportunities 
related to the vaginal microbiome should be focused on maintaining the 
Lactobacillus load in the vagina as well as preventing its passage to 
the upper regions of the reproductive tract.26 Antimicrobials can be an 
effective intervention for containing the aggressive vaginal microbiome. 
However, they should be avoided in pregnant women. Although the 
administration of metronidazole for BV results in the back shift of 
microbial profiles, this back shift results in replenishment of L. iners 
in abundance but fails to recover the L. crispatus levels.27,28 The use 
of oestrogen replacement therapy has also shown potential for treating 
urogenital infections caused by the increased colonisation of the upper 
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Source: Tjalsma et al.3 Reprinted with permission from Macmillan Publishers Ltd: Nature Reviews Microbiology ©2012.
Figure 1:  A bacterial driver–passenger model for colorectal cancer (CRC). The colonic mucosa of patients who are at risk of CRC is intrinsically 
colonised by pathogenic members of the genus Bacteroides (Enterobacteriaceae) or by bacteria that function as ‘drivers’ of CRC that cause 
inflammation, increased cell proliferation and/or the production of genotoxic substances that contribute to the accumulation of mutations 
during the adenoma-carcinoma sequence. The oncogenic process is accompanied by the rupture and bleeding of the cancerous tissue that 
alters the micro-environment and the selective pressure on local microbiota. These changes facilitate the gradual replacement of ‘driver’ bacteria 
by ‘passengers’, consisting of tumour-foraging opportunistic pathogens, commensal or probiotic bacteria, or other bacteria with a competitive 
advantage at the tumour. Tumour progression may be either suppressed (by probiotic ‘passenger’ bacteria) or promoted (by pathogenic 
‘passenger’ bacteria) as a result of these microbial colonisation shifts. 
3 Volume 110 | Number 11/12November/December 2014
South African Journal of Science  
http://www.sajs.co.za
Commentary Composition and interaction of microbiomic interventions
Page 3 of 5 
genital tract by Lactobacillus species.29 Readers are encouraged to 
refer to a recent review by MacPhee and co-workers30 in which they 
discuss the possibility and efficacy of using topically applied vaginal 
probiotics under regulations characterising their use as drugs or 
intravaginal devices.
Impact of the Human Microbiome Project in 
South Africa
The human microbiome forms one of four pillars that has a health 
impact in Africa; the other three being genetics, socio-economics 
and environmental factors.31 Figure 3 effectively displays the role and 
importance of the human microbiome in delineating the health-and-
disease model in African populations. However, South Africa (and in fact 
the African continent) has been neglected and hugely under-represented 
in the Human Genome Project and its status in the Human Microbiome 
Project is not any different. 
The role of human microbiota discussed earlier in this commentary 
covers all three major physiological areas of microbiome research – the 
surface of the skin, the gastrointestinal tract and the urogenital tract. In 
addition, one lifestyle disorder (obesity) and an infectious factor (the 
vaginal microbiome) affecting metabolism and immunity, respectively, 
are also discussed. This commentary explains the importance of 
microbiome research to understand specific physiological phenomena 
and disease susceptibility. A better understanding of (1) the lifetime 
stability of human microbiota, (2) the similarity and diversity of 
microbiota among individuals, their families, the community and the 
entire population, (3) the possibility of founding a universal microbiota 
database and, finally, (4) the microbiomal adaptation and mutation with 
changing lifestyles and environmental factors, can provide important 
insights into novel therapeutic targets and diagnostic biomarkers for 
various illnesses.31
According to a recent study, covering 188 countries over a period of 
33 years (1980–2013), published in the Lancet (29 May 2014), South 
Africa has the highest overweight and obesity rate in sub-Saharan 
Africa with 40% of men and 69% of women overweight or obese.32 The 
major reasons for obesity in South Africa are (1) easy access to a low-
cost calorie-rich diet, (2) sedentary lifestyles because of fast-growing 
urbanisation and (3) the social stigma associating ‘being-fat’ with health 
and wealth and ‘being-thin’ with HIV infection. However, the role of the 
gut microbiome in obesity cannot be overruled as the obesity-associated 
gut microbiome, e.g. Firmicutes, is significantly more capable of 
extracting energy from food than the microbiota of lean individuals and 
hence may indirectly increase the risk of concomitant cardiometabolic 
diseases such as diabetes and hypertension. Therefore, a complete 
array of experimental and analytical tools need to be generated nationally 
and regionally via a thorough gut microbiome investigation.33
Another microbiomic factor impacting the South African health system is 
the vaginal microbiome imbalance. In a recent study published in PLOS 
Medicine, it was reported that BV, due to the prevalence of pathogenic 
anaerobic and facultative bacteria such as Gardnerella vaginalis, is 
associated with a threefold increased risk of female-to-male HIV-1 
transmission. High BV prevalence in women has been associated with 
lower socio-economic status (hygiene) and in South Africa may further 
be associated with race (black women have a higher incidence of BV 
because of lower dominance of lactobacilli), sexual practices (women 
with multiple sex partners have a higher incidence), trichomoniasis, 
HIV-1 infection (leading to BV and vice versa), recent antibiotic use, 
and the absence of lactic acid and peroxide producing lactobacilli. The 
introduction of antibiotics against G. vaginalis and Atopobium vaginae 
and/or the use of lactobacilli probiotics as an adjuvant/alternative 
to antibiotic intervention may subdue the impact of BV on HIV-1 
transmission. However, maintaining a lactobacilli-predominant flora in 
the vagina appears longer lasting and more effective because of the 
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Source: Jia et al.15 Reprinted with permission from Macmillan Publishers Ltd: Nature Reviews Drug Discovery ©2008.
ChRE BP, carbohydrate response element binding protein; SRE BP1, sterol regulatory element binding protein 1; TG, triglyceride.
Figure 2:  Schematic of how the gut microbiota affects fat storage in the host. The gut microbiota increases lipoprotein lipase (LPL) activity in adipocytes to 
promote storage of calories harvested from the diet into fat through two mechanisms. In the first mechanism, (a) the gut microbiota selectively 
suppresses fasting-induced adipocyte factor (FIAF, also known as ANGPTL4), a member of the angiopoietin-like family of proteins, leading to 
the up-regulation of LPL. In the second mechanism, (b) the gut microbiota metabolises the non-digestible polysaccharides and induces de novo 
hepatic lipogenesis via the absorption of resulting monosaccharides. 
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ability of G. vaginalis and A. vaginae to form biofilms recalcitrant to 
antibiotic treatment.34,35 As stated by Cohen and co-workers34: 
A lactobacillus-predominant vaginal flora might 
not only reduce the risk of HIV-1 acquisition 
in women, but also HIV-1 transmission to male 
partners, and points to the potential benefits of 
using the human microbiota to prevent disease.
South Africa is struggling with a food allergy epidemic among black 
children. This expression or suppression of food allergy is attributed 
to the differences in intestinal microbial populations between allergic 
and non-allergic infants caused by an alarming increase in the rate of 
caesarean sections, socio-economic status and changing diet, as well as 
the frequent use of antimicrobials. The mutation and modification of the 
maternal intestinal microbial milieu may also affect the child’s microflora. 
In addition, environmental factors such as exposure to soil/dust in close 
vicinity to migrant populations may lead to hand-to-mouth transmission 
of harmful microbiota in children. Although this theory requires further 
experimentation and explanation, the role of the microbiome in food 
allergy in black South African children cannot be ignored.36
Various factors such as genetic polymorphism, pathogenic infection, 
poor nutrition and hygiene can also significantly affect the efficiency 
and efficacy of oral vaccines against pathogenic gut microbiota. In a 
typical example, the altered gut microbial composition in the case of 
IBD leads to the disruption of mucosal integrity and function, which 
in turn compromises mucosal immunity. This significantly altered gut 
physiology may directly or indirectly affect vaccine efficacy and obstruct 
the development of effective and durable mucosal immune responses.37
The human microbiome will continue to alter with age, health status, 
sickness frequency and type, and hormonal variations, as well as 
under changing physico-chemical, environmental and social factors.38 
The above-mentioned specialised conditions represent merely the tip 
of the ‘microbiomic iceberg’ impacting health in South Africa. Since 
inception of the USD100 million Human Microbiome Project in 2007, 
only a handful of studies have covered the South African microbiome 
paradigm, with the majority of studies conducted overseas. We urge the 
South African biomedical research community to join hands to unfold 
the African microbiome landscape which, given the disease prevalence 
in Africa, might prove to be the most diverse, challenging and disease 
predisposing microbiome known to humankind.
Concluding comments
The microbiome-associated diseases discussed in this commentary 
can act (in future) as a guidance point for other related or unrelated 
conditions with emphasis on the fact that the microbial supplements 
(probiotics), facilitators (prebiotics), terminators (antibiotics) and 
bacteriocins should be linked to form an effective synergistic therapeutic 
paradigm. The microbiomic interconnection between various continuous 
systems such as the gastrointestinal and respiratory systems should be 
considered and studied for their co-therapeutic potential. Furthermore, 
the very confusing and complicated scenarios arising from probiosis 
and dysbiosis as well as from probiotics and synbiotics need thorough 
laboratory and clinical investigation in order to complete the phenotypic 
profiling of related microbiome-associated diseases. From a South 
African, sub-Saharan and African perspective, the role of xenobiotic 
interventions via prebiotics, probiotics and synbiotics in special cases 
such as immunocompromised patients, neonates and children must also 
be carefully studied by taking their safety considerations into account.
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Figure 3:  A complex set of interdependent and parallel processes that govern health and susceptibility to disease. They include the role and function of 
genetic variation (central panel), epigenetic remodelling (left panel) and the microbiome (right panel), with the latter two significantly affected by 
the environment and acting as mediators of the phenotype.
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